Aqilion on Phase I results and possible IPO

Aqilion recently announced positive results from the Phase I study with AQ280. The candidate targets eosinophilic esophagitis and is being tested in Aqilion's Regulus program. CEO Sarah Fredriksson visited BioStock's studio to share more about the Phase I results and plans for a possible IPO.

Watch the interview with Aqilions vd Sarah Fredriksson, in English, below.

In the meantime, there is no need to worry about it. ”